Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroDiscovery has received ethical approval to commence a 50-patient Phase II trial for NSL-101 for periodontitis. The trial is anticipated to commence during Q4 2007.
Subscribe to our email newsletter
This study will evaluate analgesic efficacy, anti-inflammatory activity and safety of NSL-101 gel compared with the standard analgesic used in the scaling and root planing procedure for the treatment of periodontitis. The trial will take place at the Peruvian University of Cayetano Heredia in Lima.
NeuroDiscovery holds a world-wide license to NSL-101 from Ampika. The license includes agreements for the ethical retribution of a percentage of profits to the Peruvian Amazonian forest people, which will be implemented through Cambridge University, UK.
Dr Mark Treherne, NeuroDiscovery’s chairman, said: “This Phase II trial for NSL-101 is part of our strategy to identify multiple uses to commercialise this product. We also anticipate commencement of the previously approved Phase II trial for third molar extraction in the near future.”